Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Increase in circulating stem cells can be achieved through Stem-Kine: Study

Increase in circulating stem cells can be achieved through Stem-Kine: Study

Semel Institute for Neuroscience and Human Behavior awarded $14.9M for establishing new IPCN

Semel Institute for Neuroscience and Human Behavior awarded $14.9M for establishing new IPCN

Lean mass may decline among Alzheimer's patients

Lean mass may decline among Alzheimer's patients

New patient education video and guidebook for MS patients

New patient education video and guidebook for MS patients

Sun Pharmaceutical Industries' generic Namenda ANDA: USFDA grants tentative approval

Sun Pharmaceutical Industries' generic Namenda ANDA: USFDA grants tentative approval

Resverlogix highlights features of RVX-208 drug at ATVB conference

Resverlogix highlights features of RVX-208 drug at ATVB conference

Terrible tragedy for Alzheimer's suffering mother and family

Terrible tragedy for Alzheimer's suffering mother and family

GE Healthcare to present results of phase 2 study of flutemetamol at HAI Meeting

GE Healthcare to present results of phase 2 study of flutemetamol at HAI Meeting

More public-private partnerships crucial for success of Italian pharmaceutical industry

More public-private partnerships crucial for success of Italian pharmaceutical industry

Stimulating care homes can help people living with dementia

Stimulating care homes can help people living with dementia

Omega-3 fatty acids improve nerve regeneration, prevent psychotic disorders and reduce cellular aging

Omega-3 fatty acids improve nerve regeneration, prevent psychotic disorders and reduce cellular aging

Pittsburgh managing diabetes more cost effectively than other states

Pittsburgh managing diabetes more cost effectively than other states

Smoking may increase risk of MS in people who have established risk factors for MS

Smoking may increase risk of MS in people who have established risk factors for MS

Scientific evidence links high levels of copper and iron to age-related disorders

Scientific evidence links high levels of copper and iron to age-related disorders

Role of beta defensins in development of chronic inflammatory response in the brain

Role of beta defensins in development of chronic inflammatory response in the brain

ADDF, AFTD announce recipients of Frontotemporal Dementia Drug Discovery Program award

ADDF, AFTD announce recipients of Frontotemporal Dementia Drug Discovery Program award

OSU-CG12 agent kills cancer cells through energy restriction: Study

OSU-CG12 agent kills cancer cells through energy restriction: Study

Star Scientific completes Research and Royalty Agreement with SRQ Bio

Star Scientific completes Research and Royalty Agreement with SRQ Bio

Nutritional supplement can increase blood circulation of hematopoietic stem cells

Nutritional supplement can increase blood circulation of hematopoietic stem cells

ANA recognizes WOC nursing as specialty

ANA recognizes WOC nursing as specialty

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.